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Abstract
Background: Tuberculous meningitis (TBM) is a major global health problem, and it is sometimes
difficult to perform a differential diagnosis of this disease from other diseases, particularly partially-
treated pyogenic meningitis (PTPM). In an earlier study, we demonstrated the presence of a 30-kD
protein antigen in cerebrospinal fluid (CSF) of TBM patients. We have also shown that lymphocytes
from CSF of TBM patients respond differently to this antigen than do those from PTPM patients.
The purpose of this study was to develop an assay that can discriminate between TBM and PTPM.
Methods: We developed a cell enzyme-linked immunosorbant assay (Cell ELISA) to quantitatively
measure production of antibodies against the 30-kD protein in B cells from CSF of TBM and PTPM
patients.
Results:  The cell ELISA yielded 92% (11/12) sensitivity and 92% (11/12) specificity for the
differential diagnosis of TBM from PTPM.
Conclusion: When induced with the 30-kD protein antigen, B cells derived from CSF of TBM
patients respond to IgG production within 24 h while those derived from PTPM patients do not
respond.
Background
Tuberculous meningitis (TBM) is an infection of the cen-
tral nervous system (CNS) that is prevalent in both under-
developed and developing countries. An increased inci-
dence of TBM has occurred in recent years due to the
growing number of people infected with human immun-
odeficiency virus (HIV). Diagnosis of TBM remains prob-
lematic despite many new, advanced diagnostic methods
[1,2]. Previous clinical studies have clearly demonstrated
that the timing of TBM treatment is the most critical factor
in determining the ultimate outcome, which underscores
the importance of early diagnosis [3]. The laboratory con-
firmation for the diagnosis of TBM is based on the detec-
tion of acid-fast bacilli (AFB) in the cerebrospinal fluid
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(CSF) and by culturing CSF for Mycobacterium tuberculo-
sis bacilli (MTB) [4]. However, the sensitivity of direct AFB
smears from CSF ranges from 5–10% and culturing tech-
niques take 4–6 weeks. It has been recently reported that
the staining efficiency of the AFB smear test can be
increased to detect up to 50% of TBM cases, but this tech-
nique requires a very large amount of CSF [5].
Clinical as well as CSF features are helpful for diagnosing
TBM, but they cannot be used to differentiate TBM from
other infectious and non-infectious disorders [6,7]. In
particular, clinicians often encounter difficulty when per-
forming a differential diagnosis of TBM from partially-
treated pyogenic meningitis (PTPM) cases. Both the
results from biochemical and pathological analysis of CSF
and the clinical presentation of TBM are often similar to
those of PTPM, which results in frequent misdiagnosis.
In an earlier study, we reported the presence of a diagnos-
tic 30-kD protein antigen in CSF of confirmed and sus-
pected TBM patients [8]. Immunological methods such as
antibody-capture enzyme-linked immunosorbant assay
(ELISA) have been previously used for diagnosing TBM
[9]. The cell ELISA method allows further confirmation of
the results obtained by antibody-capture ELISA.
Cellular immune function is characterized by the exist-
ence of various types of lymphoid cells. As lymphocytes
participate in the production of humoral immunity, they
may respond to the 30-kD protein antigen in TBM and
PTPM patients. We have developed a cell ELISA to study
the response of B cells derived from CSF of TBM and
PTPM cases following challenge with the 30-kD protein
antigen. The purpose of the present study was to evaluate
the antibody response to the 30-kD protein antigen in
CSF of TBM and PTPM patients by cell ELISA and to deter-
mine whether this method may be used in differential
diagnosis of TBM from PTPM.
Methods
Patients and sample collection
The Central India Institute of Medical Sciences (CIIMS),
Nagpur, is a tertiary referral center. CSF was collected from
patients who were suspected of having TBM or other infec-
tions before they received any treatment. For patients
undergoing cranial surgery, analysis of CSF was per-
formed if they were suspected of having meningitis. These
patients were already on broad-spectrum antibiotics, such
as third-generation cephalosporins and aminoglycosides.
To establish a diagnosis of meningitis, 2–5 ml CSF was
withdrawn from patients using a lumbar puncture. CSF
was then subjected to routine biochemical analysis and
pathological analysis including Gram staining, India ink
staining, and AFB staining and culturing. One milliliter of
CSF was used for the cell ELISA study, and 1 ml was used
for detection of the 30-kD protein band by SDS-PAGE
analysis in 12 randomly selected TBM and PTPM patients.
Diagnosis of TBM and PTPM was based on the criteria
described below.
Diagnostic criteria
1. Tuberculous Meningitis (TBM)
Presence of Mycobacterium tuberculosis in CSF by stain-
ing and/or culture, OR
Clinical meningitis with the following observations:
A. Sub-acute or chronic fever with features of meningeal
irritation such as headache, neck stiffness, and vomiting
with or without other features of CNS involvement
B. CSF findings showing increased proteins, decreased
glucose (CSF:blood glucose ratio <0.5), and/or pleocyto-
sis with lymphocytic predominance
C. Presence of the 30-kD protein band in CSF on SDS-
PAGE analysis
D. Good clinical response to antituberculous drugs
None of the 12 TBM patients had positive AFB staining.
2. Partially-treated pyogenic meningitis (PTPM)
Presence of pathogenic bacteria in CSF by staining and/or
culture, OR
Clinical meningitis with the following observations:
A. Fever and/or signs of meningeal irritation (patients
who have undergone cranial surgery to treat tumor(s),
stroke, or head injury and who have received antibiotics),
OR High fever and/or signs of meningeal irritation with or
without CNS manifestations (patients who received
broad-spectrum antibiotics)
B. CSF findings showing increased proteins, decreased
glucose (CSF:blood glucose ratio <0.2), and/or pleocyto-
sis with a predominance of polymorphonuclear cells; CSF
may resemble that of chronic meningitis patients
C. Absence of the 30-kD protein band in CSF on SDS-
PAGE analysis
D. Good clinical response to broad-spectrum antibiotics
3. Control group
Peripheral blood samples from six healthy volunteers
were also analyzed and included as negative controls.BMC Neurology 2004, 4:16 http://www.biomedcentral.com/1471-2377/4/16
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Laboratory studies
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE
CSF samples obtained from confirmed and suspected
TBM cases were subjected to SDS-PAGE. SDS-PAGE was
performed with a vertical slab gel electrophoresis system
(Broviga, India) using the standard Laemmali method
(10). A 4% stacking gel and 10% running gel were used.
Electrophoresis was carried out at 250 volts/50 mAmps.
Gels were developed by staining with Coomassie brilliant
blue GR-250 and the protein profiles were then studied.
Band size (i.e., molecular weight) was estimated using
molecular weight markers (Genei, Bangalore, India) in a
parallel lane.
Antigen (30-kD) preparation
Following separation of proteins from CSF of confirmed
TBM patients (AFB-positive) by SDS-PAGE, the 30-kD
protein band was sliced out of the gel and pre-equili-
brated in elution buffer (0.15 M phosphate-buffered
saline [PBS], pH 7.4) and then electro-eluted in a whole
gel eluter system (Biotech, India) for 90 min at 30 volts
(11). The sample was then harvested from the unit and
dialyzed against PBS and the protein content was meas-
ured using a Bio Lab KIT. Protein purity was checked using
native PAGE and was then used to evaluate the antibody
response of B cells derived from CSF of TBM and PTPM
patients.
Preparation of CSF Cells
One milliliter of CSF collected from TBM and PTPM
patients was centrifuged at 400 rpm for approximately 20
min. The supernatant was then discarded and the cell pel-
let was washed two times with PBS and then diluted in
RPMI 11640 tissue culture medium containing 10% fetal
calf serum.
Preparation of Blood Cells
Heparinized blood samples were obtained from six
healthy volunteers. Peripheral blood mononuclear cells
(PBMC) were isolated from heparinized blood by stand-
ard Ficoll-Hypaque gradient centrifugation. PBMCs were
dissolved in PBS and centrifuged at 400 rpm for approxi-
mately 15–20 min, and the PBMCs were then diluted in
RPMI 11640 tissue culture medium containing 10% fetal
calf serum.
Cell ELISA
Flat-bottomed, 96-well ELISA plates were coated with 10
µg 30-kD antigen/ml diluted in PBS (pH 7.2). Following
overnight incubation, the plates were washed with PBS
and then coated with 5% BSA-PBS for 4 h. The plates were
then washed five times with PBS. Two-hundred µl of the
cell preparation derived from CSF of patients with TBM or
PTPM were then added to the wells and coated. Each sam-
ple was prepared in duplicate. Plates were maintained
overnight at 37°C in 5% CO2 in a carbon dioxide incuba-
tor. The following day, the plates were washed with PBS
and horseradish peroxidase (HRP)-conjugated rabbit
anti-human IgG (1:10,000) was then added to the plates.
After a 2-hr incubation at 37°C, the plates were washed
again with PBS and 100 µl tetramethylbenzidine (TMB)/
H2O2 were added. The TMB/H2O2 served as a substrate for
HRP. After a 15-min incubation, 100 µl stop solution (2.5
N sulphuric acid) were added and the plates were then
read with an ELISA reader at 450 nm (12).
Results
Detailed clinical data for TBM and PTPM patients are pre-
sented in Table 1. Out of the 12 PTPM patients, two cases
harbored microorganisms, which were cultured (gram-
positive cocci in one case and gram-negative bacilli in the
other case). Among the 12 patients who fulfilled the crite-
ria for TBM (shown in Table 1), CSF of all these patients
was positive for the 30-kD protein antigen and was nega-
tive for AFB. None of the patients had a previous history
of extra-CNS tuberculosis. In addition to the patients
described in Table 1, we also tested an additional 700 CSF
samples, including 150 from TBM patients. The 30-kD
protein antigen was observed in >90% of these TBM
patients (data not shown). Figure 1 shows the presence of
the 30-kD protein band in the CSF of suspected TBM
cases. This band was markedly absent from the CSF of
PTPM patients.
The ELISA absorbance values of IgG to the 30-kD protein
antigen in CSF from TBM and PTPM patients are pre-
sented in Figure 2. The cut-off value (OD at 450 nm) for
positivity to the 30-kD protein antigen IgG in the control
CSF is 0.6. High-titer values for IgG antibody production
against the 30-kD protein antigen were observed in 11 out
of 12 TBM patients. However, the titer in PTPM patients
was much lower than that observed in TBM patients. IgG
antibody production (expressed as ELISA absorbance
value) ranged from 0.7 to 2.0 for cells derived from CSF of
TBM patients, with the exception of case no. 5 (ELISA
absorbance value, 0.59), and from 0.05 to 0.38 for cells
derived from CSF of pyogenic meningitis cases, with the
exception of case no. 4 (ELISA absorbance value, 0.79).
The sensitivity of the cell ELISA was 92% and the specifi-
city was 92% for differential diagnosis of TBM from
PTPM. No IgG antibodies to the 30-kD protein antigen
were produced by PBMCs from six healthy individuals
within 48 h of exposure to the 30-kD protein antigen.
Discussion
During the past decade, several conventional immu-
noassays including ELISA, dot immunobinding assays,
immunoblot assays, and various molecular methods such
as the polymerase chain reaction (PCR) have beenBMC Neurology 2004, 4:16 http://www.biomedcentral.com/1471-2377/4/16
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reported as adjuncts in the diagnosis of TBM [4,13-15].
However, difficulties have been encountered when using
many of the aforementioned techniques to differentiate
TBM from PTPM. CSF TLC, DLC (total and differential
leukocyte count), protein, and glucose estimation are
helpful parameters for establishing a TBM diagnosis and
for differentiating other infectious and non-infectious
neurological disorders, but these tests are non-specific and
often cannot differentiate TBM from PTPM in patients in
whom organisms are not observed. Delays in diagnosis
and treatment are regarded as major contributing factors
to the high mortality and morbidity of TBM, and any
delay in starting appropriate medication for TBM and
PTPM worsens the outcome.
We previously used SDS-PAGE to demonstrate the pres-
ence of a 30-kD protein antigen in the CSF of TBM
patients that is specific to M. tuberculosis and may be con-
sidered to be a diagnostic marker for TBM. In this study,
we used this 30-kD protein antigen to evaluate the IgG
antibody response of B cells derived from CSF of TBM and
PTPM patients and from peripheral blood samples from
six healthy volunteers. A cell ELISA was developed for the
quantitative measurement of antibody production against
the 30-kD protein antigen by these cells. Higher titers of
IgG antibody production were observed in TBM patients
compared to PTPM patients. The cells obtained from CSF
of TBM patients gave an early response, presumably
because they were already sensitized against the TBM anti-
gen. However, when challenged with the 30-kD protein
antigen, the cells obtained from PTPM patients and
healthy volunteers gave a delayed response since they are
not sensitized against this antigen. Therefore, an early
response on this time scale is indicative of TBM.
Table 1: Clinical and CSF Findings for TBM and PTPM Patients
CSF Analysis
Case No. Age (years)/
Sex
TLC P % L % Protein 
(mg/dl)
Sugar 
(mg/dl)
CSF:blood 
sugar ratio
Neck 
Stiffness
Duration of 
fever (weeks)
Headache
TBM
1* 16/f 30 - 100 83 27 0.32 Present 16 Present
2 8/m 90 5 95 105 30 0.31 Absent 8 Present
3 54/f 25 2 98 47 67 0.54 Absent 3 Present
4 16/f 450 18 82 535 21 0.24 Absent 12 Present
5* 26/m 120 60 38 143 43 0.66 Present 12 Present
6 58/m 14 - 100 68 37 0.44 Present - Absent
7 31/f 180 12 88 203 86 0.53 Absent 1 Present
8 55/f 112 10 90 231 22 0.38 Present 4 Present
9 65/m 150 1 99 131 23 0.33 Present 4 Present
10 56/m 121 12 88 217 41 0.47 Present 2 Present
11 7/f 32 35 65 68 31 0.32 Present 4 Present
12 43/f 60 - 100 97 39 0.48 Present 2 Present
PTPM
1# 38/m 220 90 10 96 26 0.20 Present 1 Present
2# 63/f 1600 61 38 401 15 0.14 Present 1 Present
3**# 23/m 61 95 5 270 33 0.20 Absent 6 Present
4+π 25/m 180 88 12 203 86 0.53 Present 1 Present
5# 48/m 450 77 32 868 32 0.21 Present 8 Present
6π 14/f 150 84 11 61 38 0.31 Absent 1 Present
7ψ 52/m 140 92 8 471 12 0.14 Absent - Absent
8# 56/m 430 80 20 518 17 0.22 Absent - Present
9++ψ 6/m 36 82 9 61 107 0.33 Absent - Absent
10# 62/f 40 73 27 142 25 0.25 Absent - Present
11# 4/m 50 90 5 71 24 0.19 Absent - Absent
12π 27/m 200 78 22 131 21 0.18 Absent 2 Present
%P- Polymorphs, % L- Lymphocytes.
*Pulmonary tuberculosis (on chest x-ray) **Consolidation (on chest x-ray)
#Cranial surgery post operative. ψ Post Head injury, π Presented to CIIMS as PTPM.
+ gram-negative bacilli observed, ++ gram-positive& non-capsulated cocci pairs observed.BMC Neurology 2004, 4:16 http://www.biomedcentral.com/1471-2377/4/16
Page 5 of 6
(page number not for citation purposes)
We have thus shown that cell ELISA is a sensitive tech-
nique for the differential diagnosis of TBM from PTPM.
This method involves the demonstration of active anti-
body production by cells, particularly those derived from
the affected site [16]. Previously, we standardized cell
ELISA methodology in our laboratory using standard cul-
ture filtrate protein of M. tuberculosis (H37Rv strain)
received from Colorado State University, Fort Collins USA
(data not shown). The only limitation of this method is
the time period (24–30 h) involved. However, the sensi-
tivity of the test overcomes this drawback since it the only
reported method that can discriminate TBM from PTPM.
The sensitivity and specificity of IgG antibody in differen-
tial diagnosis of TBM from PTPM using the 30-kD protein
antigen by cell ELISA was found to be 92% (11/12). We
have also demonstrated that antibody production against
the 30-kD protein antigen is higher in cells derived from
CSF of TBM patients compared to PTPM patients.
Various methods have been developed in our laboratory
that yield a high specificity and sensitivity for diagnosis of
TBM, but a small number of false positive results have
been observed in pyogenic meningitis cases, particularly
PTPM cases [17,18]. The cell ELISA method developed in
our laboratory using the 30-kD protein antigen marker
can potentially provide additional information to the
treating physician that may enable a differential diagnosis
of TBM from PTPM.
The cell ELISA method for diagnosing TBM is based on the
assumption that local synthesis of humoral antibodies
against MTB antigen occurs. Various researchers have
shown that CSF-derived cells have a significantly higher
proliferation response to purified protein derivative
(PPD) in patients with TBM, which is suggestive of an
intrathecal immune response [11,19].
Our data can be summarized by the following observa-
tions: first, cell ELISA is a useful method for differentiating
TBM from PTPM using the 30-kD protein antigen; second,
the method of challenging B cells from CSF of suspected
TBM patients with the 30-kD protein antigen can be help-
ful in confirming a TBM diagnosis; and third, the cell
ELISA allows several samples to be analyzed simultane-
ously. Hence, the cell ELISA should be a very useful tool
for the differential diagnosis of TBM from PTPM.
Conclusion
The presence of a 30-kD protein antigen in CSF of TBM
patients indicates that this protein carries the candidate
marker antigen which is specific to M. tuberculosis. We
have demonstrated that by using cell ELISA, we can differ-
entiate TBM patients from PTPM patients, which should
be helpful for diagnosing TBM. Additionally our results
suggest that lymphocytes from CSF of TBM patients when
challenged with 30 kD protein give a quick response by
producing IgG antibodies when compared with that of
PTPM and healthy volunteers. This may be because
SDS-PAGE electrophoretogram of CSF from control (lanes  B, C, E) and suspected (lane D) TBM subjects Figure 1
SDS-PAGE electrophoretogram of CSF from control (lanes 
B, C, E) and suspected (lane D) TBM subjects. Molecular 
weight marker is shown in lane A. The arrow indicates the 
30-kD band, which represents the 30-kD protein antigen
B Cell response (IgG reactivity) to the 30-kD protein antigen  in CSF cells derived from tuberculous meningitis (TBM) and  partially-treated pyogenic meningitis (PTPM) patients and  peripheral blood cells from control subjects Figure 2
B Cell response (IgG reactivity) to the 30-kD protein antigen 
in CSF cells derived from tuberculous meningitis (TBM) and 
partially-treated pyogenic meningitis (PTPM) patients and 
peripheral blood cells from control subjects
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lymphocytes from TBM patients have already been
exposed to 30 kD MTB antigens.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
RSK carried out the study design, data collection, statisti-
cal analysis, data interpretation, literature search, and
manuscript preparation; NPA, RPK, and RMS assisted in
data analysis collection; NHC assisted in data collection,
statistical analysis, and data interpretation; HJP partici-
pated in the preparation of the manuscript, data interpre-
tation, and study design; GMT provided assistance in
preparation of the manuscript, data interpretation, study
design, and funds collection; and HFD supervised the
study design, statistical analysis, data interpretation, man-
uscript preparation, and literature search.
Acknowledgements
We would like to acknowledge the help of Colorado State University, Fort 
Collins, USA and the US NIH, NIAID Contract No. 1 AI-75320, entitled 
"Tuberculosis Research Materials and Vaccine Testing."
References
1. Leonard JM, Des Prez RM: Tuberculous meningitis. Infect Dis Clin
North Am 1990, 4:769-787.
2. Thwaties GE, Chau TT, Mai NT: Tuberculous meningitis. J Neuro
Neurosurg Psychiatry 2000, 68:289-99.
3. Kennedy DH, Fallon RJ: Tuberculous meningitis.  JAMA 1979,
241:264-268.
4. Katti MK: Immunodiagnosis of tuberculous meningitis: rapid
detection of Mycobacterial antigens on cerebrospinal fluid
by reverse passive hemagglutination assay and their charac-
terization by Western blotting.  FEMS Immunol Med Microbial
2001, 31:59-64.
5. Thwaites GE, Caws M, Chau TT, Dung NT, Campbell JI, Phu NH,
Hien TT, White NJ, Farrar JJ: Comparison of Conventional Bac-
teriology with Nucleic Acid Amplification (Amplified Myco-
bacterium Direct Test) for Diagnosis of Tuberculous
Meningitis before and after Inception of Antituberculosis
Chemotherapy. J Clin Microbial 2004, 42(3):996-1002.
6. Newton RW: Tuberculous meningitis:.  Arch Dis Child 1994,
70:364-366.
7. Ahuja G, Mohan K, Prasad K, Behari M: Diagnostic criteria for
tuberculous meningitis and their validation. Tubercle Lung Dis
1994, 75:149-152.
8. Kashyap RS, Biswas SK, Agarwal N, Chandak N, Purohit H, Taori GM,
Daginawala HF: Significance of 30 KD protein marker as diag-
nostic marker in CSF of Tuberculous meningitis. Ann Ind Acad
Neurl 2001, 4:197-201.
9. Kashyap RS, Satpute RM, Kainthla RP, Purohit HJ, Chandak N, Taori
GM, Daginawala HF: Demonstration of IgG antibodies to 30 Kd
protein antigen in CSF for diagnosis of TBM by antibody cap-
turing ELISA. Neurol India 2004, 52(3):359-62.
10. Laemmali UK: Cleavage of structural proteins during the
assembly of the head of bacteriphage T4.  Nature 1970,
227:68-685.
11. Rosenkrands I, Rasmussen PB, Carnio M, Jacobnsen S, Thwiesen M,
Andersen P: Identification and charecterization of a 29 kilodal-
ton protein from Mycobacterium tuberculsois culture fil-
trate Recognized by mouse memory effector cells. Infection
and Immunity 1998, 66(6):2728-2735.
12. Baig SM: Anti-purified protein derivative Cell Enzyme Linked
immunosorbent assay, a Sensitive method for early diagno-
sis of Tuberculos meningitis. Journal of Clinical Microbiology 1995,
33(11):3040-3041.
13. Wagle N, Vaidya A, Joshi S, Merchant SM: Detection of tubercle
antigen in cerebrospinal fluids by ELISA for diagnosis of
tuberculous meningitis. Indian J Pediatr 1990, 57:679-83.
14. Mathai A, Radhakrishanan VV, Sarda C, George SM: Detection of
heat stable mycobacterial antigen in cerebrospinal fluid by
Dot-Immunobinding assay. Neurol India 2003, 51(1):52-54.
15. Katti MK: Assessment of antibody responses to antigens of
mycobacterium tuberculosis and Cysticercus celluloseae in
cerebrospinal fluid of chronic meningitis patients for defini-
tive diagnosis as TBM/NCC by passive hemaggltination and
immunoblot assays. FEMS Immunol Med Microbial 2002, 33:57-61.
16. Malashkhia YA, Geladze MG: Autoradiographics studies of cul-
tures of Cerebro Spinal Fluid lymphocytes in non suppura-
tive meningitis. Neurology  1976, 26:1081-1084.
17. Kashyap RS, Agarwal N, Chandak NC, Taori GM, Biswas SK, Purohit
HJ, Daginawala HF: The application of Mancini technique as a
diagnostic test in CSF of tuberculous meningitis patients.
Med Sci Monit 2002, 8:MT95-98.
18. Kashyap RS, Kainthla RP, Biswas SK, Agarwal N, Chandak N, Purohit
HJ, Taori GM, Daginawala HF: Rapid diagnosis of tuberculous
meningitis using the simple Dot ELISA method. Med Sci Monit
2003, 9:MT123-126.
19. Kinnman J, Fryden S, Eriksson S, Moller E, Link H: Tuberculous
meningitis :immune reactions within central nervous
system. Scand J Immunol 1981, 13(3):289-96.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2377/4/16/prepub